Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Germany

 

German labs accused of lobbying to profiteer from Covid

A group of journalists from German broadcasting companies Westdeutscher Rundfunk (WDR) and Norddeutscher Rundfunk (NDR) and German daily newspaper Süddeutsche Zeitung (SZ) has accused Germany’s private labs groups of lobbying the government in order to protect their Covid testing profits. 

German reforms “could kill PE outpatient investment”

German health minister Karl Lauterbach offered a politicised Christmas present in December with an announcement he would stop “locust investors” buying up outpatient medical practices. A German VC source tells HBI this could “kill” private equity investment in German healthcare, and push innovation elsewhere.

Sanoptis targets Spain for expansion

Sanoptis, Germany’s second largest ophthalmology group by revenue, is looking to expand in Spain, and beyond, and looking at targets to buy.

Pressure grows to restrict investment in German health care

Pressure is growing for a change in German law restricting who can invest in healthcare. If enacted, it could effectively see some outpatient operators “banned”, and restrict who can do telehealth. Is such a development likely? HBI speaks to a trio of German healthcare experts to find out more.

Economy makes Fresenius breakup unlikely

Speculation persists over the break-up of bloated conglomerate Fresenius by new CEO Michael Sen, but HBI hears that looks increasingly unlikely given the current economic climate. So, what are Sen's options? HBI talks to a well-placed investment banker to find out more.

EDG sale “in early stages”

HBI understands that the sale of pan-European and dentist-led European Dental Group (EDG) has begun, and is in its very early stages. 

Helios makes digital-only presence in Kenya and Colombia

Curalie, the digital health subsidiary of German hospital group Fresenius Helios, has launched new digital-only operations in Kenya and Colombia. Experts tell HBI this is a good way for Helios to access new markets, but likely won’t lead to a hospital boom any time soon.

Find Us